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OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) has been 
available in a film formulation since 2010 for the treatment of opioid 
dependence. A clinical trial showed that patients preferred the film to tablet 
formulation. Insurance claims data extracted from MarketScan Medicaid 
database were analyzed to compare patient persistence and health care costs 
between the two formulations. METHODS: Patients initiating treatment with 
BUP/NAL after the launch of film (September 2010) were classified in two groups 
according to formulation of initial prescription: film or tablet. Time to treatment 
discontinuation and monthly health care costs by treatment phase (before 
treatment, initiation period, during treatment, discontinuation period, after 
discontinuation and reinitiation period) were compared between the two groups, 
adjusting on baseline characteristics (demographics, comorbidities, treatment, 
and resource utilization before treatment). RESULTS: Analysis included 450 
patients initially treated with film and 1127 with tablet, followed over 6.3 and 8.0 
months on average respectively. Of those treated with tablet, 17.8% of patients 
switched to film. The average dose at initiation was 16 mg in both groups. 
Kaplan-Meier estimates of the probability of persistence 200 days were 59.11% 
and 51.46% in the film and tablet groups respectively. The hazard ratio for 
treatment discontinuation with film versus tablet, adjusted on baseline 
characteristics, was 0.72 (p=0.02). Monthly costs were highest around the time of 
treatment initiation, switch and discontinuation. Monthly costs during 
treatment were $418.76 for patients treated with film and $477.66 with tablet 
(p=0.1561). Monthly costs after treatment discontinuation were 40% lower among 
patients treated with film (p=0.0354). CONCLUSIONS: Patients treated with 
BUP/NAL film appear to have a lower probability of early treatment 
discontinuation. Treatment with the film formulation may generate cost savings 
since costs around discontinuation are relatively high, and costs after treatment 
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OBJECTIVES: Given bipolar disorder (BPD) and schizophrenia impose a 
significant burden in the workplace, this study evaluated the annual costs 
among US employees with BPD or schizophrenia. METHODS: Analysis of 2001-
2012 HCMS database from subjects with BPD/schizophrenia diagnostic claims 
and ≥12 months follow-up after their index-date and subjects without 
BPD/schizophrenia (controls). Index date was defined as: (i) initial claim date for 
subjects with BPD or schizophrenia and (ii) average of BPD and schizophrenia 
index date by year for controls. Inflation-adjusted annual costs including 
medical, Rx, sick leave (SL), short-term disability (STD) and workers’ 
compensation (WC) were compared between cohorts using two-part regression, 
controlling for confounders. RESULTS: Total annual costs among BPD subjects 
(n=5299) were higher compared to controls (n=653,707) in 2001 (+$8573) and 2011 
(+$9547), respectively. Differences were significant (P<0.005) in all costs 
categories in 2001 (Medical=$4701, Rx=$2252, SL=$391, STD=$762, and WC=$461) 
and in 2011(Medical=$6147, Rx=$2552, SL=$208 and STD=$413). Total costs, 
medical costs and Rx costs were higher among schizophrenia (n=391) subjects 
than controls in the years 2001 (+$8,812, +$6549 and +$2119), and 2011 (+$7772, 
+$5191, and +$2630), respectively. In 2001, BPD subjects’ costs were $239 lower 
than schizophrenia despite significantly higher STD (+$649) and WC (+$666) 
costs. In 2011, however, subjects with BPD incurred greater costs than those with 
schizophrenia ($1775; P>0.05). From years 2001-2011, BPD subjects’ medical costs 
increased (+$1950) and STD costs decreased (-$473). Consistent decreases in STD 
costs were observed among the BPD subjects since 2006, and direct medical costs 
as a percent of total costs increased from 78.9%-86.7% for BPD subjects and from 
75.2%-78.8% for controls. CONCLUSIONS: In this employer database, STD costs 
have become marginally lower since 2006. However, medical costs (e.g., 
ER/inpatient visits) among these patient populations still remain high, 
suggesting the need for therapeutic options with a lower medical cost burden.  
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OBJECTIVES: To evaluate the impact of metabolic comorbidities on health care 
resource utilization and costs in hospitalized patients with schizophrenia. 
METHODS: A retrospective observational study was conducted utilizing data 
from the Premier Perspective Database™ from October 1, 2010 to May 31, 2012. 
Patients with an admitting primary or secondary diagnosis of schizophrenia 
during the study period were eligible for inclusion. Patients were classified as 
having 0, 1, 2, or 3+ metabolic comorbidities based upon diagnoses of diabetes 
mellitus, hyperglycemia, hypertension, dyslipidemia, coronary heart disease, 
ischemic heart disease, or cardiovascular disease (CVD) during their index 
hospitalization. Generalized linear models were used to compare costs across 
the 4 comorbidity cohorts (0, 1, 2, 3+). Logistic regressions were used to compare 
the likelihood of readmission and the likelihood of death among the comorbidity 
cohorts. RESULTS: A total of 57,506 patients met all inclusion criteria; 33.9% with 
0 comorbidities, 26.7% with 1 comorbidity, 19.9% with 2 comorbidities, and 19.4% 
with 3 or more comorbidities. Among patients with comorbidities, 57% had 
hypertension, 28% had diabetes, 30% had hyperlipidemia, 10% had 
coronary/ischemic heart disease, 4% had CVD, and 2% had hyperglycemia. As the 
number of comorbidities increased from 0 to 3+, there were increases in medical 
costs ($9,619 to $13,111; P<0.0001), pharmacy costs ($501 to $1,540; P<0.0001), and 
total costs ($10,120 to $14,651; P<0.0001). Patients with a higher number of 
comorbidities were more likely to have a readmission for any cause (9% to 13%; 
P<0.0001) and die during their index hospitalization (0.3% to 2%; P<0.0727), 
although increases in mortality were not statistically significant. CONCLUSIONS: 
A high prevalence of metabolic comorbidities was found in this study population 
of hospitalized schizophrenia patients. An increase in the number of metabolic 
comorbidities had adverse clinical and economic consequences, including 
increased costs and readmission rates.  
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OBJECTIVES: To estimate the indirect costs for community-dwelling Texas 
residents with schizophrenia. METHODS: This was a retrospective database 
study using Medical Expenditure Panel Survey (MEPS) data from 2005 to 2008. 
The proportion of the total national indirect costs for ‘all mental illnesses’ (based 
on DSM IV criteria) that were attributable to Texas patients was estimated and 
this ratio was applied to the national indirect costs for schizophrenia (ICD9 code 
of 295) to estimate costs attributable to Texas patients. Categories for indirect 
costs included: restricted activity-associated costs (based on number of work 
days missed), reduced employment costs (based on difference in wages for 
patients with versus without schizophrenia), premature mortality costs (based 
on percentage of patients who commit suicide times discounted wages lost), and 
caregivers’ costs (based on days of work missed by an unpaid caregiver). These 
estimates were adjusted to 2008 dollars and summed to obtain the 2005-2008 
total 4-year indirect costs for patients with schizophrenia in Texas. All analyses 
were carried out using the ‘survey’ procedure of SAS in order to account for the 
complex sample design of MEPS. RESULTS: For community-dwelling patients 
with schizophrenia in Texas (weighted n = 153,872 patient years), the mean 
indirect costs per patient year were about $17,000. The estimated productivity 
cost per patient-year due to reduced employment, premature mortality, 
restricted activity and caregivers’ cost was $16,572, $215, $67, and $50 
respectively. The total indirect costs for patients with schizophrenia in this 
Texas population between 2005 and 2008 amounted to about $2.6 billion, or 
about $650 million per year. These estimates did not include costs for homeless, 
institutionalized, or incarcerated patients. CONCLUSIONS: This study highlights 
the high financial burden of indirect costs for community-dwelling patients with 
schizophrenia, most of which were due to reduced employment.  
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OBJECTIVES: Schizophrenia-related costs in the US have been estimated at over 
$60 billion annually. Although state Medicaid plans cover a large percent of the 
population with schizophrenia, other non-Medicaid state budgets are 
responsible for covering the costs for patients who are incarcerated or admitted 
to state-operated inpatient mental health facilities. The purpose of the study was 
to estimate the annual direct and indirect costs for Texas Medicaid patients with 
schizophrenia. METHODS: Direct costs were estimated from the perspective of 
the state of Texas as payer using data from 2006-2008 adjusted to 2008 US 
dollars. Direct Texas Medicaid costs were extracted from claims files (about 9,000 
patients per year). State-operated inpatient mental health facility costs were 
provided in aggregated form by the Texas Department of State Health Services. 
Data from the Bureau of Justice Statistics and recent literature were used to 
estimate incarceration costs. Medical Expenditure Panel Survey data from 2005-
2008 were used to estimate indirect costs per patient-year. Direct costs to the 
patient (e.g. travel and unreimbursed expenses) were not captured. RESULTS: 
The schizophrenia-related mean annual per patient cost was estimated at 
$31,511 - direct and indirect costs were $14,607 (46.3%) and $16,904 (53.7%), 
respectively. Direct costs to Medicaid, state-operated inpatient mental health 
facilities, and jails accounted for 31.6%, 1.1%, and 13.6% of total costs, 
respectively. Most of the indirect costs (98%) were due to morbidity-associated 
productivity losses, with the remaining small portion were due to mortality-
associated productivity losses (early death/suicide), and unpaid caregivers’ lost 
productivity. CONCLUSIONS: This was the first study that estimated both direct 
and indirect costs of schizophrenia in the Texas Medicaid population. Direct 
medical costs paid by Medicaid accounted for only about one-third of total costs. 
These cost estimates may help health care providers and policymakers better 
understand the economic burden of schizophrenia.  
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OBJECTIVES: Opioid poisoning has increased substantially over the past decade, 
and has been associated with increases in opioid prescribing. This has been 
accompanied by intervention efforts aimed at preventing and reversing opioid 
